Altimmune Inc Q2 2024 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Liam Hiester - Piper Sandler - Analyst : This is Liam Hiester on for Yas. Just a few quick questions. So the first one, if you could kindly talk about the response rate in fibrosis and MASH resolution that you believe to be competitive in the MASH space? Secondly, what are your expectations for the dose response across the 1.2 milligram to 1.8-milligram dosing for biopsy endpoints. And then third, going into the end of Phase 2 meeting with the FDA, what are some key questions you plan to discuss with them? And if you can provide any color on which patient population you are considering for Phase 3 would be great.

Question: Seema Shoran - Evercore Group L.L.C. - Analyst : Hi. This is Seema on for Lisa. Thank you for taking my question. As you're expecting Phase 2 MASH data in first quarter, can you expand on how the enrollment is going and when you expect it to be complete? And my second question is, on oral pemvidutide. You have mentioned that, you plan to announce a candidate by year-end. Is that still the case? And what are some of the characteristics of this candidate that you are looking for? Thank you.